BioSpace News Archive

Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced plans to present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, California.

Protagonist Therapeutics, Inc. (Nasdaq: PTGX) (“Protagonist” or “the Company”) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will offer a corporate presentation and host one-on-one meetings with investors at the 41st Annual J.P. Morgan Healthcare Conference, taking place January 9-12 in San Francisco, California.

Protalix BioTherapeutics, Inc. announced that the Company’s management and Board of Directors have decided that it is in the best interest of the Company to voluntarily delist its common stock from the Tel Aviv Stock Exchange.

Integra LifeSciences Holdings Corporation, a leading global medical technology company, announced that Jan De Witte, president and chief executive officer will present at the 41st Annual J.P. Morgan Healthcare conference on January 11, 2023 at 7:30pm ET.

AptarGroup, Inc. (NYSE: ATR), a global leader in drug delivery, consumer product dispensing and active material science solutions and services, announced their participation at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023.

Quipt Home Medical Corp., a U.S. based home medical equipment provider, focused on end-to-end respiratory care, announced its fourth quarter and fiscal year 2022 financial results and operational highlights.

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, announced its support for a recent guideline update by the International Society for Heart and Lung Transplantation (ISHLT), which includes the use of donor-derived cfDNA (dd-cfDNA) testing for surveillance of heart transplant recipients.

Land Science®, a division of REGENESIS® and the leading provider of contaminant vapor mitigation systems, has been granted a U.S. patent for the inventive use of reinforced geomembrane that features an encapsulated metalized layer and is installed with NitraCore™, a nitrile-modified asphalt spray coating.

Minovia Therapeutics, a clinical-stage global biotechnology company, today announced that the findings of the first clinical use of mitochondrial augmentation therapy (MAT) platform to treat pediatric patients with primary mitochondrial diseases have been published in Science Translational Medicine.

The New England Journal of Medicine has published results from a positive Phase 3 trial showing adults and adolescents treated with Dupixent® 300 mg weekly experienced significant improvements in signs and symptoms of eosinophilic esophagitis, which were sustained for up to one year.